CD19 Targeting in gMG: Mechanistic Rationale for Upstream B-Cell Depletion

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder driven by pathogenic autoantibodies targeting proteins at the neuromuscular junction, leading to fluctuating weakness and fatigue. As the treatment landscape evolves, increasing attention has been placed on therapies that intervene earlier in the immunopathogenic cascade, particularly those targeting B-cell populations responsible for autoantibody production.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, spoke with NeurologyLive® about the phase 3 MINT trial evaluating inebilizumab, a CD19-targeting monoclonal antibody. In this discussion, Nowak provides clinical and mechanistic context for how this therapy differs from existing approaches and why upstream B-cell targeting may represent a meaningful shift in disease management.

In this episode, Nowak reviews the role of autoreactive B cells in AChR-positive gMG and explains how CD19-directed depletion captures a broader range of pathogenic cells, including those not targeted by CD20 therapies, offering a rationale for improved disease control.